Adenovirus replication in tumor cells

"Adenovirus replication in tumor cells" refers to the use of genetically engineered adenoviruses that can selectively replicate within cancer cells by exploiting tumor-specific mutations (such as in p53 or pRB pathways) or using tumor-selective promoters to control essential viral genes. Upon replication, these viruses induce lysis of the cancer cell (oncolysis), propagate to neighboring malignant cells, and may promote antitumor immune responses. The approach is a foundation of oncolytic virotherapy in cancer; however, replication is governed by multiple viral and cellular factors, and is not in itself a single druggable molecular target. Safety, specificity, and the immune response remain central challenges in clinical development. This entry should ideally map to more precise molecular targets such as individual adenoviral proteins (E1A, E1B, ADP) or their interaction partners (p53, pRB) for structured data.

Other names

Oncolytic adenovirus replicationTumor-selective adenovirus replicationReplicating adenoviral therapy in cancerOncolytic virotherapy (adenoviral subtype)

Selective replication in tumor cells leading to cancer cell lysis (oncolysis); Stimulation of antitumor immune response; Tropism modification for enhanced tumor selectivity; Apoptosis induction via interaction with tumor suppressor pathways (e.g., p53, pRB)